The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.
The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...
HealthDay on MSN12d
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver CancerFor patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback